The Chronic Disease Conundrum - Summary - MDSpire
Feature

The Chronic Disease Conundrum

Russ Lebovitz and Arnon Chait on why we need smarter biomarkers to guide clinically actionable diagnostics in an aging population

  • By

  • Jessica Allerton

  • May 14, 2026

  • 7 min

Share

Healthcare systems face challenges with traditional diagnostics as aging populations and chronic diseases rise. Experts Russ Lebovitz and Arnon Chait emphasize the urgency for advanced, biology-based diagnostics, particularly in detecting neurodegenerative diseases and cancers. They advocate for utilizing biomarkers to identify conditions earlier and accurately, thus shifting from reactive to proactive care. Improved diagnostics could lead to more targeted treatments and cost-effective healthcare, ultimately enhancing patient outcomes as chronic disease burden increases.

Original Source(s)

The Chronic Disease Conundrum

  • by Jessica Allerton

  • May 14, 2026

Related Content

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.